Skip to main content

Table 2 Characteristics of patients, laboratory findings, and treatment for sepsis according to study group

From: Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: a propensity-matched cohort study

Variables Unmatched group Matched group
All patients
(n = 1,723)
non-PMX-HP
(n = 1,201)
PMX-HP
(n = 522)
SD P value All patients
(n = 524)
non-PMX-HP
(n = 262)
PMX-HP
(n = 262)
SD P value
Primary infection site, n (%)
 Abdomen 618 (35.9) 321 (26.7) 297 (56.9) 0.642 <0.001 226 (43.1) 113 (43.1) 113 (43.1) 0.000 1.000
 Lung/thorax 385 (22.3) 323 (26.9) 62 (11.9) 0.387 <0.001 93 (17.7) 47 (17.9) 46 (17.6) 0.010 0.909
 Urinary tract 268 (15.6) 189 (15.7) 79 (15.1) 0.017 0.751 97 (18.5) 46 (17.6) 51 (19.5) 0.049 0.574
 Bone/soft tissue 192 (11.1) 147 (12.2) 45 (8.6) 0.119 0.029 52 (9.9) 28 (10.7) 24 (9.2) 0.051 0.559
 Cardiovascular 31 (1.8) 27 (2.2) 4 (0.8) 0.122 0.043 7 (1.3) 3 (1.1) 4 (1.5) 0.033 0.705
 Central nervous system 26 (1.5) 25 (2.1) 1 (0.2) 0.179 0.019 1 (0.2) 0 (0.0) 1 (0.4) 0.088
 Catheter-related 30 (1.7) 27 (2.2) 3 (0.6) 0.142 0.024 6 (1.1) 4 (1.5) 2 (0.8) 0.072 0.421
 Others 34 (2.0) 27 (2.2) 7 (1.3) 0.068 0.219 8 (1.5) 3 (1.1) 5 (1.9) 0.062 0.481
 Unknown 139 (8.1) 115 (9.6) 24 (4.6) 0.195 0.001 34 (6.5) 18 (6.9) 16 (6.1) 0.031 0.723
Microorganisms, n (%)
 Gram-negative bacteria 656 (38.1) 429 (35.7) 227 (43.5) 0.159 0.002 230 (43.9) 113 (43.1) 117 (44.7) 0.031 0.725
 Gram-positive coccus 402 (23.3) 311 (25.9) 91 (17.4) 0.207 <0.001 105 (20.0) 50 (19.1) 55 (21.0) 0.048 0.585
 Fungus 23 (1.3) 18 (1.5) 5 (1.0) 0.049 0.373 8 (1.5) 5 (1.9) 3 (1.1) 0.062 0.481
 Mixed infection 232 (13.5) 142 (11.8) 90 (17.2) 0.154 0.003 72 (13.7) 39 (14.9) 33 (12.6) 0.067 0.447
 Others 29 (1.7) 20 (1.7) 9 (1.7) 0.005 0.930 9 (1.7) 3 (1.1) 6 (2.3) 0.088 0.323
 Unknown 371 (21.5) 272 (22.6) 99 (19.0) 0.091 0.088 100 (19.1) 52 (19.8) 48 (18.3) 0.039 0.657
Laboratory tests on admission to the ICU
 WBC, 109/L 10.8 (3.6–17.7) 11.8 (5.0–18.1) 7.4 (2.2–16.1) 0.188 <0.001 10.4 (3.4–18.5) 11.6 (4.6–18.1) 9.7 (2.7–18.8) 0.012 0.195
 Platelet counts, 109/L 108 (58–174) 113 (60–186) 99 (53–154) 0.189 <0.001 100 (54–164) 92 (52–162) 108 (57–167) 0.100 0.126
 Hb, g/L 10.5 (2.5) 10.6 (2.5) 10.4 (2.4) 0.099 0.063 10.4 (2.5) 10.3 (2.7) 10.5 (2.4) 0.081 0.355
 PT-INR 1.4 (1.2–1.7) 1.4 (1.2–1.6) 1.5 (1.3–1.8) 0.122 <0.001 1.4 (1.3–1.8) 1.4 (1.2–1.8) 1.4 (1.3–1.8) 0.091 0.477
 PRBC administration, n (%) 889 (51.6) 546 (45.5) 343 (65.7) 0.416 <0.001 313 (59.7) 159 (60.7) 154 (58.8) 0.039 0.656
 Surgical intervention, n (%) 795 (46.1) 450 (37.5) 345 (66.1) 0.598 <0.001 289 (55.2) 146 (55.7) 143 (54.6) 0.023 0.792
Other therapeutic intervention, n (%)
 rhsTM 571 (33.1) 329 (27.4) 242 (46.4) 0.401 <0.001 203 (38.7) 101 (38.5) 102 (38.9) 0.008 0.929
 AT III concentrate 653 (37.9) 353 (29.4) 300 (57.5) 0.591 <0.001 241 (46.0) 121 (46.2) 120 (45.8) 0.008 0.930
 Protease inhibitors 209 (12.1) 117 (9.7) 92 (17.6) 0.231 <0.001 64 (12.2) 33 (12.6) 31 (11.8) 0.023 0.790
 Heparinoids 69 (4.0) 44 (3.7) 25 (4.8) 0.056 0.275 23 (4.4) 11 (4.2) 12 (4.6) 0.019 0.831
 IVIG 619 (35.9) 360 (30.0) 259 (49.6) 0.410 <0.001 224 (42.7) 117 (44.7) 107 (40.8) 0.077 0.377
 Low-dose steroid 568 (33.0) 333 (27.7) 235 (45.0) 0.365 <0.001 196 (37.4) 101 (38.5) 95 (36.3) 0.047 0.588
 RRT 627 (36.4) 352 (29.3) 275 (52.7) 0.489 <0.001 245 (46.8) 121 (46.2) 124 (47.3) 0.023 0.793
 Non-renal indication RRT 189 (11.0) 45 (3.7) 144 (27.6) 0.694 <0.001 53 (10.1) 26 (9.9) 27 (10.3) 0.013 0.885
  1. Data are presented as mean (standard deviation), median (first quartile to third quartile), or number (percentage)
  2. AT antithrombin, Hb hemoglobin, IVIG intravenous immunoglobulins, PMX-HP polymyxin B hemoperfusion, PRBC packed red blood cells, PT-INR prothrombin time-international normalized ratio, rhsTM recombinant human soluble thrombomodulin, RRT renal replacement therapy, SD standardized difference, WBC white blood cell count